| 產(chǎn)品名稱 |
pDG3 |
| 商品貨號(hào) |
B219505 |
| Designations |
pDG3 |
| Depositors |
Allelix Biopharmaceuticals, Inc., G Strachan, Allelix Biopharmaceuticals, Inc. |
| U.S. Patent |
|
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Biosafety Level |
1 |
| Host |
Distribution host: Escherichia coli JM83; K-12 strain JM83 |
| Vector Information |
Size (kb): 7.8000001907348630 Vector: pDG3 (plasmid) Construction: pUC12, Tn5, pBB116 Marker(s):ampR,neoR,argB Construct size (kb): 7.800000190734863 Features: marker(s): ampR, neoR, argB
replicon: pMB1 |
| Applications |
integrating vector shuttle vector vector permitting positive selection for integration |
| Comments |
Restriction digests of the clone give the following sizes (kb): HindIII/SalI--3.1, 1.65, 1.3, 0.75, 0.5 + smaller; XbaI--4.4, 3.4; EcoRI--7.8; SmaI--4.3, 3.5; SphI--7.8. This is an integrative, selectable vector conferring arginine prototrophy on arginine autotrophic hosts such as Aspergillus niger 350(-)52, ATCC 20739 (argB-). It also confers kanamycin resistance. This was constructed by inserting a HindIII/SalI fragment of Tn5 into pUC12 cut with HindIII/SalI (pNE02) and then inserting an XbaI fragment from pBB116 into the XbaI site of pNE02. |
| Media |
ATCC® Medium 1227: LB Medium (ATCC medium 1065) with 50 mcg/ml ampicillin
|
| Growth Conditions |
Temperature: 37.0°C |
| References |
Buxton FP, et al. Aspergillus niger transformation system. US Patent 4,885,249 dated Dec 5 1989
Berse B, et al. Cloning and characterization of the ornithine carbamoyltransferase gene from Aspergillus nidulans. Gene 25: 109-117, 1983. PubMed: 6363209
|
| Shipped |
freeze-dried |
| Shipping Information |
Distributed: freeze-dried |
